Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-17T06:07:10.225Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of central antagonist of cholecystokinin-1 receptors GB-115 on cognitive functions in patients with Generalized Anxiety Disorder

Published online by Cambridge University Press:  01 September 2022

O. Dorofeeva ,
M. Metlina ,
A. Chepeliuk  and
M. Vinogradova
O. Dorofeeva*
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
M. Metlina
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
A. Chepeliuk
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
M. Vinogradova
Affiliation:
Lomonosov Moscow State University, Department Of Neuro- And Pathopsychology, Faculty Of Psychology, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Generalized anxiety disorder (GAD) is associated with reduced attention, inhibition, decrease of processing speed. The impact of a new peptide antagonist of central cholecystokinin-1 receptors (GB-115) on cognitive processes in patients with GAD is reported.

Objectives

To research the cognitive effects of GB-115 in patients with GAD.

Methods

25 patients with GAD in ICD-10 (mean age 35,76±8,55 years) treated with GB-115 in clinically relevant dose (6 mg/d) were enrolled to the study. The evaluation of cognitive functions was conducted at background, Day 3, Day 7, Day 14 and Day 21. The laboratory test toolkit included reaction time test, Shulte-Platonov tables, attention tests (using hardware and software complex “NeuroSoft-PsychoTest”). Statistical significance was ascertained by Wilcoxon signed-rank test.

Results

Speed of reaction time increased on the Day 7 (418,17±61,49 msec, p≤0,01), the Day 14 (422,25±70,69 msec, p≤0,01) and the Day 21 of treatment (406,5±52,79 msec, p≤0,01) in comparison with background (449,19±64,91). Attention parameters improved on the Day 3 (305,95±45,31 msec, p≤0,05) and the Day 21 of treatment (300,14±47,74 msec, p≤0,05) in comparison with the background (316,41±42,35 msec). Decrease of time in performance of tables of Shulte-Platonov was also observed on the Day 7 (59,40±13,71 sec, p≤0,01), the Day 14 (57,88±12,82 sec, p≤0,01) and the Day 21 (53,40±13,19 sec, p≤0,01) in comparison with the background (68,84±16,78 sec).

Conclusions

GB-115 revealed cognitive effects such as an increase of processing speed and improvement of different aspects of attention (attentional resource allocation, attention span and switching) after the Day 7 of treatment.

Disclosure

No significant relationships.

Keywords

anxiety disordercholecystokininanxiolyticcognitive functions
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S186
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.